These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 2292704)

  • 21. An open-label pilot study of oral S-adenosyl-L-methionine in major depression: interim results.
    Rosenbaum JF; Fava M; Falk WE; Pollack MH; Cohen LS; Cohen BM; Zubenko GS
    Psychopharmacol Bull; 1988; 24(1):189-94. PubMed ID: 3387521
    [No Abstract]   [Full Text] [Related]  

  • 22. The effect of S-adenosylmethionine on CNS gene expression studied by cDNA microarray analysis.
    Cavallaro RA; Fuso A; D'Anselmi F; Seminara L; Scarpa S
    J Alzheimers Dis; 2006 Aug; 9(4):415-9. PubMed ID: 16917150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antidepressant activity of S-adenosylmethionine.
    Caruso I; Fumagalli M; Boccassini L; Sarzi Puttini P; Ciniselli G; Cavallari G
    Lancet; 1984 Apr; 1(8382):904. PubMed ID: 6143204
    [No Abstract]   [Full Text] [Related]  

  • 24. An open-label pilot study of oral S-adenosylmethionine in major depression. An interim report.
    Rosenbaum JF; Fava M; Falk WE; Pollack MH; Cohen LS; Cohen BM; Zubenko GS
    Ala J Med Sci; 1988 Jul; 25(3):301-6. PubMed ID: 3052138
    [No Abstract]   [Full Text] [Related]  

  • 25. Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease.
    Morrison LD; Smith DD; Kish SJ
    J Neurochem; 1996 Sep; 67(3):1328-31. PubMed ID: 8752143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. S-adenosylmethionine in depression. A literature review and preliminary report.
    Janicak PG; Lipinski J; Davis JM; Comaty JE; Waternaux C; Cohen B; Altman E; Sharma RP
    Ala J Med Sci; 1988 Jul; 25(3):306-13. PubMed ID: 3052139
    [No Abstract]   [Full Text] [Related]  

  • 27. Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis. A double-blind, placebo-controlled study.
    Frezza M; Surrenti C; Manzillo G; Fiaccadori F; Bortolini M; Di Padova C
    Gastroenterology; 1990 Jul; 99(1):211-5. PubMed ID: 2188871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Controlled double-blind study (SAMe-imipramine) in depressive syndromes].
    Mantero M; Pastorino P; Carolei A; Agnoli A
    Minerva Med; 1975 Nov; 66(78):4098-101. PubMed ID: 1103017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Homocysteine metabolism and cerebrospinal fluid markers for Alzheimer's disease.
    Popp J; Lewczuk P; Linnebank M; Cvetanovska G; Smulders Y; Kölsch H; Frommann I; Kornhuber J; Maier W; Jessen F
    J Alzheimers Dis; 2009; 18(4):819-28. PubMed ID: 19661622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased cerebrospinal fluid cortisol level in Alzheimer's disease is not related to depression.
    Hoogendijk WJ; Meynen G; Endert E; Hofman MA; Swaab DF
    Neurobiol Aging; 2006 May; 27(5):780.e1-780.e2. PubMed ID: 16198445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid antidepressant response with SAMe. A double-blind study.
    Potkin SG; Bell K; Plon L; Bunney WE
    Ala J Med Sci; 1988 Jul; 25(3):313-6. PubMed ID: 3052140
    [No Abstract]   [Full Text] [Related]  

  • 32. The antidepressant potential of oral S-adenosyl-l-methionine.
    Rosenbaum JF; Fava M; Falk WE; Pollack MH; Cohen LS; Cohen BM; Zubenko GS
    Acta Psychiatr Scand; 1990 May; 81(5):432-6. PubMed ID: 2113347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation.
    Jacobsen S; Danneskiold-Samsøe B; Andersen RB
    Scand J Rheumatol; 1991; 20(4):294-302. PubMed ID: 1925418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New trends in the therapy of chronic liver diseases. Significance of Sam-dependent transmethylations].
    Garassini G; Sarnari V
    Minerva Gastroenterol; 1974; 20(1):19-26. PubMed ID: 4827982
    [No Abstract]   [Full Text] [Related]  

  • 35. Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study.
    Freund Levi Y; Vedin I; Cederholm T; Basun H; Faxén Irving G; Eriksdotter M; Hjorth E; Schultzberg M; Vessby B; Wahlund LO; Salem N; Palmblad J
    J Intern Med; 2014 Apr; 275(4):428-36. PubMed ID: 24410954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of various S-adenosylmethionine preparations on histamine methylation in vitro and in vivo.
    Reilly MA; Schayer RW
    Agents Actions; 1978 Jun; 8(4):332-6. PubMed ID: 685755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determinants of the essential one-carbon metabolism metabolites, homocysteine, S-adenosylmethionine, S-adenosylhomocysteine and folate, in cerebrospinal fluid.
    Smith DE; Smulders YM; Blom HJ; Popp J; Jessen F; Semmler A; Farkas M; Linnebank M
    Clin Chem Lab Med; 2012 Mar; 50(9):1641-7. PubMed ID: 22962226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Open trial of S-adenosylmethionine for treatment of depression.
    Lipinski JF; Cohen BM; Frankenburg F; Tohen M; Waternaux C; Altesman R; Jones B; Harris P
    Am J Psychiatry; 1984 Mar; 141(3):448-50. PubMed ID: 6367496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switch and S-adenosylmethionine.
    Carney MW; Chary TK; Bottiglieri T; Reynolds EH
    Ala J Med Sci; 1988 Jul; 25(3):316-9. PubMed ID: 3052141
    [No Abstract]   [Full Text] [Related]  

  • 40. Early clinical double-blind study with S-adenosyl-L-methionine: a new potential antidepressant.
    Küfferle B; Grünberger J
    Adv Biochem Psychopharmacol; 1982; 32():175-80. PubMed ID: 7046363
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.